Our Approach
ZYUS is primarily focused on the development, patent protection and regulatory approval of its drug product candidates through clinical trials. Simultaneously, ZYUS is committed to offering patients immediate access to its foundational products for compassionate reasons.
Pharmaceutical Drug Product Candidates
The development, protection, and regulatory approval of our pharmaceutical drug product candidates from authorities such as the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Health Canada. Followed by commercialization of these proprietary drug products for use in treatment of specific diseases and indications.
Access to Foundational Products
While the primary focus is on the clinical development of ZYUS' regulatory approved pharmaceutical drug product candidates, we also are engaged in the commercialization of our exempt market therapeutics such as cannabinoid oils, softgel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Evidence-based Approach
Committed to delivering clinically validated therapies that have the potential to improve patient outcomes.
Robust Intellectual
Property Portfolio
Patent protection secured in 30 countries, including the U.S., Canada, and EU for formulation used in Trichomylin® softgel capsules.
Differentiated Drug Pipeline
Advancing polypharmacolog-ical, non-opioid therapies targeting chronic and neuropathic pain.
Quality in
Manufacturing
Canadian-based manufacturing and purification facility, designed to meet cGMP standards, reduces the risk of supply chain disruptions.
Insider Confidence
Insider investment CAD$70M+, demonstrating strong conviction in ZYUS’ disruptive potential.
Patient Well-being
Developing drug candidates focused on urgent unmet needs in chronic and neuropathic pain.